Jack Cuzick

Jack Cuzick led the IBIS breast cancer prevention trials demonstrating that aromatase inhibitors reduce breast cancer incidence by 50 percent in high-risk postmenopausal women, and conducted the landmark meta-analysis proving that daily aspirin reduces long-term cancer incidence and mortality. His Tyrer-Cuzick breast cancer risk prediction model is the most widely used clinical tool for identifying women who benefit from chemoprevention. He has contributed to HPV-based cervical cancer screening strategies adopted by multiple countries.